中国经济网北京9月4日讯 今日，广发基金管理有限公司发布关于公司旗下部分基金估值调整情况的公 告。 公告称，自2025年9月3日起，广发基金管理有限公司对旗下基金（ETF 除外）持有的"芯原股份"（股票 代码：688521）、"中芯国际"（股票代码：688981）按指数收益法进行估值调整。同时，对ETF联接基 金持有的相关标的ETF，考虑上述股票估值调整因素对标的ETF份额净值的影响后，按当日调整后的份 额净值进行估值。 ...

为保护投资者的利益，根据《中国证监会关于证券投资基金估值业务的指导意见》（证监会公告[2017] 第13号）、中国证券投资基金业协会《关于发布中基协（AMAC）基金行业股票估值指数的通知》（中 基协发[2013]13号）的有关规定，富国基金管理有限公司（以下简称"本公司"）与基金托管人协商一 致，决定对本公司旗下基金（ETF除外）持有的"中芯国际"（证券代码：688981）进行估值调整，自 2025年09月03日起按指数收益法进行估值。基金的申购、赎回价格均以估值方法调整后当日计算的基金 资产份额净值为准。 待上述股票复牌且其交易体现了活跃市场交易特征后，将恢复采用按市场价格进行估值，届时将不再另 行公告。 特此公告。 为保护投资者的利益，根据《中国证监会关于证券投资基金估值业务的指导意见》（证监会公告[2017] 第13号）、中国证券投资基金业协会《关于发布中基协（AMAC）基金行业股票估值指数的通知》（中 基协发[2013]13号）的有关规定，富国基金管理有限公司（以下简称"本公司"）与基金托管人协商一 致，自2025年09月03日起，决定对富国上证科创板50成份交易型开放式指数证券投资基金联接基金持有 ...

Group 1 - The core point of the announcement is that Yimi Fund Management Co., Ltd. will adjust the valuation method for its funds holding the suspended stock "Huahong Company (code: 688347)" to the "index yield method" starting from August 25, 2025 [1] - The adjustment will remain in effect until the stock demonstrates active market trading characteristics, at which point the valuation will revert to using the closing price of the day without further announcement [1]

Group 1 - The core point of the announcement is that Changjin Hexin Fund Management Co., Ltd. will adjust the valuation method for its fund holdings in Huahong Semiconductor Co., Ltd. (stock code: 688347) starting from August 22, 2025 [1] - The new valuation method will utilize the "index return method" as per the guidelines from the China Securities Association Fund Valuation Working Group for suspended stocks [1] - Once the stock resumes trading and exhibits active market trading characteristics, the valuation will revert to using the closing price of the day without further announcements [1]

Group 1 - The core point of the article is that GF Fund Management Co., Ltd. has announced an adjustment in the valuation of certain funds under its management, effective from August 22, 2025 [1] - The adjustment will apply to the stock "Huahong Company" (stock code: 688347), which will be valued using the index yield method [1] - For ETF-linked funds holding the relevant ETFs, the valuation will consider the impact of the stock valuation adjustment on the net asset value of the ETFs on the adjustment date [1]

Group 1 - The announcement from Zhongyou Chuangye Fund Management Co., Ltd. indicates a valuation adjustment for the stock of Huahong Company (stock code: 688347) held by its funds [1] - Starting from August 22, 2025, the company will adopt the "index income method" for the valuation of Huahong Company stock [1] - Once the stock resumes trading and demonstrates active market trading characteristics, the company will revert to market price valuation without further announcements [1]

Group 1 - The core point of the article is that Minsheng Jia Yin Fund Management Co., Ltd. announced an adjustment in the valuation method for its funds, specifically for the stock of China Shenhua Energy Company Limited, effective from August 7, 2025 [1] - The company will use the "index income method" for valuing the stock until it resumes trading and shows active market trading characteristics, at which point it will revert to market price valuation without further announcement [1] - As of the second quarter of 2025, Minsheng Jia Yin only holds 189,600 shares of China Shenhua through its Minsheng Jia Yin CSI Mainland Resource Theme Index Securities Investment Fund A [1]

Group 1 - The core point of the announcement is that Guotou Ruijin Fund Management Co., Ltd. will adjust the valuation of its funds based on the AMAC industry index starting from August 7, 2025, specifically for the suspended stock China Shenhua (code: 601088) using the "index income method" [1] - The adjustment is in accordance with the guidelines from the China Securities Regulatory Commission regarding the valuation of securities investment funds [1] - The company will revert to market price valuation once the stock resumes trading and demonstrates active market trading characteristics, without further announcements [1] Group 2 - According to China Shenhua's A-share Q2 2025 report, Guotou Ruijin has two funds holding the stock: Guotou Ruijin CSI Upstream Resource Industry Index Securities Investment Fund (LOF) A with 326,400 shares and Guotou Ruijin CSI Hong Kong Stock Connect Central State-Owned Enterprise Dividend Index Fund A with 9,000 shares [1]

Core Viewpoint - The valuation of NuoHui Health has been drastically reduced by multiple public funds, with Da Cheng Fund setting the latest valuation at HKD 0.55 per share, marking the lowest valuation to date [2][3][4]. Group 1: Valuation Adjustments - Da Cheng Fund announced a new valuation of HKD 0.55 per share for NuoHui Health, effective from July 31, 2025, following a series of previous adjustments [3][4]. - The valuation of NuoHui Health has been cut from HKD 14.14 per share before its suspension to HKD 0.55, representing a decline of over 96% [4]. - Other public funds, including Baoying, Penghua, and Bosera, have also significantly reduced their valuations of NuoHui Health, with Bosera valuing it at HKD 3.33 per share [4][6]. Group 2: Background and Context - NuoHui Health was once a leading stock in the Hong Kong market, known for cancer screening, with a market capitalization exceeding HKD 40 billion [6]. - The company has been suspended since March 2024 due to allegations of financial fraud and audit concerns raised by Deloitte [6][7]. - The inability to timely disclose financial reports has led to ongoing valuation adjustments by various fund companies since mid-2023 [6]. Group 3: Industry Insights - The continuous downward adjustment of NuoHui Health's valuation reflects a generally pessimistic outlook on its prospects for resuming trading and heightened market vigilance regarding potential risks [7]. - Fund managers adjust valuations to ensure the fair value of fund net assets and protect investor interests, especially when market prices do not accurately reflect intrinsic value [5][7]. - The actions taken by fund companies indicate a trend towards improved risk monitoring and control within the industry [8][9].

Core Viewpoint - The valuation of Nohow Health has been significantly reduced by multiple public funds, with Dachen Fund recently announcing a valuation of HKD 0.55 per share, marking the lowest valuation to date [1][3]. Valuation Adjustments - Dachen Fund's valuation of Nohow Health has been adjusted multiple times since its suspension in March 2024, dropping from HKD 14.14 per share to HKD 0.55 per share, representing a decline of over 96% [3][5]. - Other public funds, including Baoying, Penghua, and Bosera, have also reduced their valuations of Nohow Health, with Bosera maintaining a valuation of HKD 3.33 per share, which is still above HKD 2 per share [3][6]. Market Context - Nohow Health was once a leading stock in the Hong Kong market for cancer screening, with a market capitalization exceeding HKD 40 billion [5]. - The company has faced scrutiny over financial fraud allegations, leading to its suspension and inability to disclose timely financial reports [5][6]. Fund Management Perspective - The adjustments in valuation by fund managers aim to ensure the fairness and accuracy of fund net values, protecting investor interests [4][5]. - Continuous downward adjustments reflect a pessimistic outlook on Nohow Health's prospects for resumption of trading and heightened market vigilance regarding potential risks [6].